Laboratory markers and germ cell tumors.

Area of Science:

• Oncology
• Biochemistry
• Genetics

Background:

• The 1997 International Germ Cell Consensus Classification (IGCCC) for testicular germ cell tumors (TGCT) utilized three serum tumor markers: lactate dehydrogenase (S-LD), alpha fetoprotein (S-AFP), and human chorionic gonadotropin (S-hCG).
• These markers are crucial for staging and prognosis in TGCT, and their application extends to ovarian and extragonadal germ cell tumors.

Purpose of the Study:

• To evaluate the clinical relevance of a fourth serum tumor marker, serum lactate dehydrogenase isoenzyme 1 (S-LD-1), in TGCT.
• To assess the utility of a new prognostic model incorporating S-LD-1 with the IGCCC for predicting TGCT patient survival.

Main Methods:

• Analysis of S-LD-1 levels in patients with TGCT, comparing their prevalence in seminoma versus nonseminoma subtypes.
• Development and validation of a novel staging model combining IGCCC criteria with S-LD-1 measurements.
• Correlation of serum tumor marker profiles with underlying biological characteristics, including chromosomal abnormalities (chromosome 12p amplification) and histological differentiation.

Main Results:

• Serum lactate dehydrogenase isoenzyme 1 (S-LD-1) is elevated more frequently in seminoma patients compared to S-AFP and S-hCG.
• Nonseminoma patients exhibit higher S-AFP levels more often than S-LD-1 and S-hCG.
• A new model integrating IGCCC and S-LD-1 demonstrates superior survival prediction compared to existing staging systems.

Conclusions:

• S-LD-1 represents a valuable addition to the established serum tumor markers for TGCT management.
• The distinct biological origins of S-LD-1 (chromosomal abnormality) versus S-AFP and S-hCG (histological differentiation) explain their differential clinical behavior.
• The combined IGCCC and S-LD-1 model offers enhanced prognostic accuracy for testicular germ cell tumors.